A Phase 3, Randomized, Double-Blind Study Comparing The Efficacy And Safety Of Sage-217 Plus An Antidepressant Versus Placebo Plus An Antidepressant In Adults With Major Depressive Disorder
Posted Date: Jan 6, 2021
- Investigator: Caleb Adler
- Specialties: Depression, Psychiatry/Psychology
- Type of Study: Drug
This is a randomized, double-blind, parallel-group, placebo-controlled study in adults with MDD. The diagnosis of MDD must be made according to Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Trial Version (SCID 5-CT) performed by a qualified healthcare professional.
Criteria:
Male Or Female Between 18 And 64 Years Of Age, Inclusive
Keywords:
Major Depressive Disorder (Mdd), Depression
For More Information:
Emily Rummelhoff
513-558-4295
emily.rummelhoff@uc.edu